Roche Unveils Global First: China Accelerator Building Officially Launched

Sep 29, 2023 17:46 CST Updated 17:46

Roche

Oncology Drug Research, Development, and Manufacturing

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Source: Medical Representative

Tonight, I'm sharing a major event from Roche.

If there is one leader and bellwether in the global pharmaceutical field, it is undoubtedly Roche. Every move it makes draws the attention of the industry. This week,F. Hoffmann-La Roche Ltd's global board of directors, along with a group of senior executives, visited China, drawing significant attention from the industry.Many friends can't help but ask, what major event is Roche planning this time?

It is reported that the global senior executives of Roche not only visited the government, but also had in-depth exchanges with partners and internal talents.One of the key parts of the agenda ——That is to attend the completion ceremony of Roche China Accelerator Building!

Four years later, Dr. Severin Schwan led the "Roche Executive Team" on their first visit to China, prompting many to remark on how much Roche values the Chinese market.

Dr. Schwan, Chairman of the Board of Roche Group

"I have personally experienced the innovative vitality and enormous potential here. We not only view China as an important market,More dedicated to making China an innovation hub through open collaboration, bringing better healthcare solutions to patients in China and globally. The Roche China Accelerator is a testament to empowering the local innovation ecosystem."We hope to join hands with partners in the ecosystem to accelerate innovation and benefit more patients."

Shanghai's pharmaceutical industry professionals should remember that, in the past two years,The ivory-white building of Roche, located in Shanghai's Zhangjiang High-Tech Park, has always maintained an air of mystery.It was unclear what it was for, but today the mystery has finally been revealed.

This is Roche's major project in China, with an investment of nearly 300 million yuan — the Roche China Accelerator Building.The fact that it can attract senior executives from around the world to attend the ceremony shows how much Roche values this project. After all, this is Roche's first independently established and operated accelerator globally.

What is an accelerator? Friends can understand it as an incubator, where start-up companies can access Roche's full range of local resources, including research, early development, and commercialization. This newly built accelerator building, constructed at great cost, will provide advanced laboratory and office space for start-ups, accelerating the transformation of cutting-edge results and helping Chinese R&D go global.

Such dedication and commitment are truly admirable. We see that, as a century-old multinational pharmaceutical company, Roche has been committed to providing advanced treatment solutions for Chinese patients in China. Now,Roche further boosts R&D in China's pharmaceuticals industry, supports startups to join the accelerator, and explores the frontiers of medicine together.

The completion of the accelerator will boost the transformation of innovative achievements in China and also give rise to more globally influential pharmaceutical innovations with Chinese characteristics.

Today, the inauguration ceremony of the Roche China Accelerator Building was held at the Zhangjiang High-Tech Park in Shanghai. Dr. Severin Schwan, Chairman of the Board of Directors of Roche Group, Dr. Thomas Schinecker, Global CEO of Roche Group, members of the Roche Group Board and leadership team, the Roche China leadership team, representatives from Zhangjiang Group, as well as representatives from accelerator partner organizations attended the event and witnessed this milestone moment.

The brand-new Roche China Accelerator building, crafted with dedication over two years, is located in the core area of the Zhangjiang High-Tech Park in Pudong New Area, Shanghai, with a total area exceeding 5,000 square meters.As the first accelerator independently established and operated by Roche globally, the Roche China Accelerator has invested nearly 300 million RMB, integrating Roche's own resources and advantages.With an agile and flexible cooperation model, targeted resources including funding channels, collaboration opportunities, R&D experience, and advanced laboratory equipment are provided to startups. Personalized support is offered to startups in fields such as innovative drugs, diagnostics, personalized medicine, and artificial intelligence, helping transform scientific research achievements into practical applications. Since its launch,More than a dozen companies have emerged from hundreds of enterprises to become accelerator member companies, and have reached 10 early-stage R&D collaborations with Roche China Innovation Center to jointly explore new scientific directions and technology platforms.

The accelerator building ingeniously connects laboratories, office areas, and public spaces, meeting the flexible needs of入驻的初创企业 for research and office work.

The building achieves green energy savings through environmentally friendly technologies such as an efficient envelope structure, lighting system, energy recovery, and temperature control. After the completion of the Roche China Accelerator Building, which combines excellent laboratory design quality with sustainable architectural features, it will help start-ups overcome challenges and incubate innovative scientific research results that can occupy a leading position globally. This will promote the development of Zhangjiang's new innovative ecosystem and Shanghai's science and technology innovation center, contributing to the establishment of a world-class medical industry cluster with international influence in China.

Walking into the accelerator building, you can see a well-lit, spacious and bright office area, as well as meeting rooms equipped with multimedia devices, allowing scientists to work and communicate more efficiently.

The design of the diverse spaces in Roche China Accelerator Building is even more commendable. Considering that scientists spend most of their time here, the design balances work and leisure. The outdoor area is spacious, surrounded by greenery, and several communication spaces are cleverly connected, offering a smooth, open, bright, and transparent environment full of vitality without losing aesthetic appeal. This kind of space design, which combines nature, technology, and humanity, will undoubtedly promote the exchange of ideas among scientists and inspire more innovative inspiration.

It is worth mentioning that the Accelerator Building was upgraded and constructed on the original site of Roche's Shanghai R&D Center. As early as 2004, Roche established an R&D center in China, which was the first R&D center set up by Roche in an emerging market and also the first wholly foreign-owned R&D center established by a multinational pharmaceutical company in Shanghai.In 2019, Roche invested an additional 863 million RMB to upgrade the R&D center into the brand-new Roche Shanghai Innovation Center.In 2021, the Roche China Accelerator, with an investment of 300 million RMB, was launched in Shanghai with the support of the government and partners.In 2022, to further promote innovation in China and increase R&D investment, Roche Shanghai Innovation Center (RICS) was officially upgraded to Roche China Innovation Center (CICoR)., with independent decision-making authority in new drug research and early development, covering the R&D of new drugs in disease areas such as immunology and oncology, continuously developing innovative medicines for patients in China and globally.

Dr. Shen Hong, Head of Roche China Innovation Center, stated: "As a pharmaceutical company driven by innovation, Roche has always maintained continuous investment in R&D. The completion of the Roche China Accelerator building represents the continuation and inheritance of Roche's innovative legacy in this land. In the future,We will continue to spare no effort in providing practical help to local startups, hoping that under the leadership of Dr. Tang Qiuyong, the accelerator and outstanding startups can spark more innovative ideas and produce more breakthrough innovations. While benefiting more patients in China, we also aim to help Chinese R&D go global.”

Roche's ties with China date back nearly a century.As one of the earliest multinational enterprises to start operations in China,Roche has always been committed to the long-term promise for the Chinese market and patients,Providing top-tier differentiated drugs and diagnostic solutions for Chinese patients, empowering the construction of China's healthcare innovation ecosystem.Among large multinational pharmaceutical companies, Roche is the first to establish a complete pharmaceutical value chain in China, encompassing research, development, production, marketing, and other key segments to meet the unmet needs of Chinese patients.As required.

Ms. Bian Xin, President of Roche Pharmaceuticals China, stated: "Roche always adheres to the principle of 'acting on patients' needs first,' bringing cutting-edge innovative solutions to patients in China."We look forward to the completion of the Roche China Accelerator, where more innovative achievements will be born and benefit patients in China and around the world at the earliest opportunity.We will also continue to collaborate with multiple partners to focus on building an innovative, cooperative, and diverse healthcare ecosystem in China, jointly contributing to the grand blueprint of 'Healthy China 2030'."

END

Bill Gates Invests, Surgical Robotics Company to Delist

Chairman Banned for 10 Years! Listed Company Fined 85.7 Million Yuan

5T MRI: Unveiling the Unseen, Unlocking New Scenarios for Whole-Body MRI

Integration: Leading Imaging Equipment Companies in China Continuously Drive the "Digital and Intelligent" Development of Healthcare

Medical-Engineering Collaboration: Huashivision Partners with Beihang University to Build an Ophthalmic Medical Engineering and Precision Diagnosis and Treatment Laboratory

China's Leading AI Imaging Company Collaborates with Global Imaging Giant

Top 10 Global Interventional Devices, Major Expansion in Production Capacity

438 Billion, GE Healthcare Makes a Big Move

Two Major Imaging Giants Join Hands to Invest in a New Field

BusinessBusiness cooperation email: qxzj@landianyiliao.com